Answers are grounded in this paper and cite their sources.
Background People who use drugs (PWUD) are at increased risk of blood-borne viral infections. Evidence on hepatitis C virus (HCV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV) among PWUD in Palestine is limited. This study determined the seroprevalence of HCV, HBV, and HIV among PWUD attending governmental substance use disorder (SUD) treatment centers in the West Bank. Methods This retrospective cross-sectional study included 397 PWUD in SUD treatment centers in the West Bank during 2019–2023. Serological results for anti-HCV, HBsAg, and anti-HIV were obtained from routine clinical records. Crude and adjusted prevalence ratios (PRs) for the association between injecting drug use and anti-HCV seropositivity were estimated using modified Poisson regression. Results HCV seroprevalence was 23.0%, HBsAg prevalence was 2.0%, and no HIV was detected. HCV seroprevalence was 55.4% among injecting versus 6.7% among non-injecting users. After adjustment for age, education, employment status, and previous treatment attempts, injecting drug use remained strongly associated with HCV seropositivity (adjusted PR = 6.43, 95% CI 3.82–10.82). HCV prevalence increased with longer duration of drug use (p for trend <0.001), and varied significantly across governorates. Conclusions HCV is the predominant infection among PWUD receiving SUD treatment in the West Bank, whereas HBV prevalence was low and HIV was not detected. Injecting drug use was strongly associated with HCV seropositivity, and prevalence increased with longer duration of drug use. Integrating HCV screening, RNA testing, antiviral treatment, and harm-reduction policies into SUD services is essential to achieve the WHO 2030 hepatitis elimination targets.
No takes yet. Share an insight, caveat, or question.
Habash et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: